ArticleFrontiers in immunology2025
Inflammatory burden in dialysis patients: the role of alpha defensin.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The major neutrophilic peptide alpha-defensin plays a pivotal role in atherogenesis. Atherosclerosis is more frequent in dialysis patients, increasingly ascribed to chronic low-grade inflammation. We investigated the potential association between dialysis treatment and circulating alpha-defensin levels. Methods: In a cohort of hemodialysis (HD) patients, plasma alpha-defensin concentrations were determined immediately before and after a dialysis session. Blood samples were also tested for CBC, CRP, lipid profile, and troponin levels. Body weight change, Urea Reduction Ratio and Kt/V were used to assess dialysis adequacy. Patients were divided into two groups based on alpha-defensin increase post dialysis. Groups were compared for dialysis adequacy, CBC, CRP, LDL levels, and the incidence of new documented coronary artery narrowing post HD initiation. The study was approved by the local IRB and all patients were consented. Results: A total of 37 HD patients (55% males, median age 66.5 (60.3-78 years)) were recruited. There was a marked surge in median alpha-defensin levels after HD [11,571 Conclusion: HD is an alpha-defensin generating procedure. Patients are potentially predisposed to atherosclerosis because of their enhanced alpha defensin secretion. alpha-defensin might evolve as a potential therapeutic target for atherosclerosis mitigation in this high-risk population. However, this remains to be validated in future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.